Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04724980 · ClinicalTrials.gov registry record · Phase 1

Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis

A Phase 1 study of Recurrent Respiratory Papillomatosis and Papillomavirus Infections, sponsored by Precigen.

Active
Registry status
Phase 1
Development phase
38
Enrollment target
1
Study location

NCT04724980 is a Phase 1 study of Recurrent Respiratory Papillomatosis and Papillomavirus Infections that is active but no longer recruiting, run by Precigen. The registered enrollment target is 38 participants, above the 32-participant average among 6 other Recurrent Respiratory Papillomatosis trials with a reported enrollment target (19% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04724980, a Phase 1 study of Recurrent Respiratory Papillomatosis and Papillomavirus Infections, is active but no longer recruiting, sponsored by Precigen.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
38 participants
Enrollment target
1
Study location

Study Summary

This is a Phase 1/2 study in patients with a Recurrent Respiratory Papillomatosis (RRP) disease burden that requires repeated surgical procedures for management. RRP is a rare disease caused by the human papillomavirus (HPV). Participants with a pathologically confirmed diagnosis of papilloma and a clinical diagnosis of RRP will be screened for this protocol.

Conditions Studied

Recurrent Respiratory Papillomatosis Papillomavirus Infections Papillomaviridae

Interventions

  • DRUG PRGN-2012 - Phase I; Dose Level 1
  • DRUG PRGN-2012 - Phase I; Dose Level 2
  • DRUG PRGN-2012 - Phase II; Dose Level 2

Study Locations (1)

Maryland

  • National Institutes of Health Clinical Center - Bethesda

Trial Details

FieldValue
Enrollment Target 38 participants
Start Date 2021-03-16
Est. Completion 2026-06-05
Phase Phase 1

Sponsor

Precigen

5 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04724980

The ClinicalTrials.gov registry entry for NCT04724980 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 32-participant average among 6 other Recurrent Respiratory Papillomatosis trials with a reported enrollment target (19% higher). The listed sponsor is Precigen, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Recurrent Respiratory Papillomatosis appearing as the primary indexed condition, and to 3 interventions - of which PRGN-2012 - Phase I; Dose Level 1 is the first listed.

NCT04724980 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT04724980 about?

NCT04724980 is a clinical study titled "Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis". This is a Phase 1/2 study in patients with a Recurrent Respiratory Papillomatosis (RRP) disease burden that requires repeated surgical procedures for management. RRP is a rare disease caused by the human papillomavirus (HPV). Participants with a pathologically confirmed diagnosis of papilloma and a ...

What is the current status of trial NCT04724980?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2021-03-16. Estimated completion is 2026-06-05.

What conditions does trial NCT04724980 study?

This clinical trial studies the following conditions: Recurrent Respiratory Papillomatosis, Papillomavirus Infections, Papillomaviridae.

What interventions are being tested in trial NCT04724980?

The interventions under investigation include: PRGN-2012 - Phase I; Dose Level 1 (DRUG), PRGN-2012 - Phase I; Dose Level 2 (DRUG), PRGN-2012 - Phase II; Dose Level 2 (DRUG).

Who is sponsoring clinical trial NCT04724980?

This trial is sponsored by Precigen, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04724980 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Recurrent Respiratory Papillomatosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Recurrent Respiratory Papillomatosis

All registered trials for this condition

Papillomavirus Infections

All registered trials for this condition

Maryland

All trials with a study site in Maryland

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.